In Vitro: PKRA83 (1 µg/mL) effectively reduces PK2-induced microvascular endothelial cell branching in vitro. PKRA83 (2 μM, 24 h) blocks the neuroprotective action of rPK2 in dopaminergic N27 cells (rPK2 protects N27 cell against MPP+-induced dopaminergic neuronal cell death).
In Vivo: PKRA83 (20 mg/kg; i.p) shows anti-tumor activity in the context of glioblastoma xenograft tumor models. PKRA83 (15 mg/kg; i.p, daily for 2 weeks) inhibits arthritis in mice with collagen-induced arthritis.